• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

有限剂量免疫疗法用于ECOG评分为2且PDL-1高表达的晚期非小细胞肺癌老年患者。

Limited doses of immunotherapy use in advanced non-small cell lung cancer elderly patients with ECOG of 2 and high PDL-1 expression.

作者信息

Wong Pui Yee, How Soon Hin, Hassan Radhiana, Abdul Azih Muhammad Naimmuddin

机构信息

Department of Respiratory Medicine Hospital Tengku Ampuan Afzan Kuantan Malaysia.

Department of Medicine Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia.

出版信息

Aging Med (Milton). 2021 Oct 24;4(4):345-349. doi: 10.1002/agm2.12179. eCollection 2021 Dec.

DOI:10.1002/agm2.12179
PMID:34964016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8711218/
Abstract

Immunotherapy is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with high PDL-1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.

摘要

免疫疗法是治疗晚期非小细胞肺癌（NSCLC）且PDL-1高表达患者的有效方法。在此，我们报告了三例此类患者，尽管接受了有限剂量的免疫疗法，但仍有持久疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/9572f6dc7254/AGM2-4-345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/d97b9346feed/AGM2-4-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/4a38e749dbf3/AGM2-4-345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/9572f6dc7254/AGM2-4-345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/d97b9346feed/AGM2-4-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/4a38e749dbf3/AGM2-4-345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f48/8711218/9572f6dc7254/AGM2-4-345-g002.jpg

相似文献

1
Limited doses of immunotherapy use in advanced non-small cell lung cancer elderly patients with ECOG of 2 and high PDL-1 expression.有限剂量免疫疗法用于ECOG评分为2且PDL-1高表达的晚期非小细胞肺癌老年患者。
Aging Med (Milton). 2021 Oct 24;4(4):345-349. doi: 10.1002/agm2.12179. eCollection 2021 Dec.
2
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.一线帕博利珠单抗治疗 PD-L1 高表达（≥50%）且一般状况较差的非小细胞肺癌患者的结局。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-001007.
3
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
4
Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.三例身体状况较差的局部晚期非小细胞肺癌患者对免疫治疗的拉撒路型反应：病例系列及文献综述
Ann Palliat Med. 2021 Jan;10(1):210-219. doi: 10.21037/apm-20-2279.
5
Does the Combined Use of Aspirin and Immunotherapy Result in Better Outcomes in Non-Small Cell Lung Cancer Than Immunotherapy Alone?与单独使用免疫疗法相比，阿司匹林与免疫疗法联合使用在非小细胞肺癌中是否能带来更好的疗效？
Cureus. 2022 Jun 13;14(6):e25891. doi: 10.7759/cureus.25891. eCollection 2022 Jun.
6
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.程序性死亡配体1表达阴性的晚期非小细胞肺癌的免疫治疗：文献综述
Transl Lung Cancer Res. 2024 Feb 29;13(2):398-422. doi: 10.21037/tlcr-23-144. Epub 2024 Feb 28.
7
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
8
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.纵向深度放射组学与临床资料的整合可改善对晚期 NSCLC 患者接受抗 PD-1/PD-L1 免疫治疗持久获益的预测。
J Transl Med. 2023 Mar 5;21(1):174. doi: 10.1186/s12967-023-04004-x.
9
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.ECOG 体能状况 2 分的晚期非小细胞肺癌患者的一线免疫治疗：意大利胸部肿瘤学会国际专家小组会议的结果。
ESMO Open. 2022 Feb;7(1):100355. doi: 10.1016/j.esmoop.2021.100355. Epub 2021 Dec 16.
10
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.纳武利尤单抗或帕博利珠单抗治疗晚期非小细胞肺癌患者的肿瘤PD-L1表达及临床结局：台湾地区的真实世界数据
J Cancer. 2018 Apr 19;9(10):1813-1820. doi: 10.7150/jca.24985. eCollection 2018.

本文引用的文献

1
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.阿替利珠单抗用于 PD-L1 选择的 NSCLC 患者的一线治疗。
N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346.
2
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.一线帕博利珠单抗治疗 PD-L1 高表达（≥50%）且一般状况较差的非小细胞肺癌患者的结局。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-001007.
3
Keynote 42: Pembrolizumab, PD-L1, and where to draw the line.
主题演讲42：帕博利珠单抗、程序性死亡受体1配体（PD-L1）以及如何划定界限。
Ann Transl Med. 2020 Apr;8(7):517. doi: 10.21037/atm.2020.01.65.
4
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.帕博利珠单抗治疗体力状态 2（PePS2）的非小细胞肺癌患者：一项单臂、2 期临床试验。
Lancet Respir Med. 2020 Sep;8(9):895-904. doi: 10.1016/S2213-2600(20)30033-3. Epub 2020 Mar 19.
5
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.免疫检查点抑制剂在老年非小细胞肺癌患者中的真实世界应用和生存结局。
Cancer. 2020 Mar 1;126(5):978-985. doi: 10.1002/cncr.32624. Epub 2020 Jan 14.
6
An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors.一名转移性非小细胞肺癌对纳武单抗反应异常的患者：病例报告及长期幸存者文献综述
Case Rep Oncol Med. 2019 Dec 5;2019:1816472. doi: 10.1155/2019/1816472. eCollection 2019.
7
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
8
Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients.两名晚期非小细胞肺癌患者在停止纳武单抗治疗后出现持久反应，且无疾病进展或毒性反应。
J Oncol Pharm Pract. 2020 Apr;26(3):761-767. doi: 10.1177/1078155219867131. Epub 2019 Aug 18.
9
Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients.早期 PD-1 治疗停药在转移性癌症患者中的应用。
Oncology. 2019;96(3):125-131. doi: 10.1159/000493193. Epub 2018 Oct 31.
10
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.非小细胞肺癌治疗的（变）革：十年进展及未来展望
Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017.